BPC-157: what it is and what studies found

The detailed research

The detailed research on BPC-157 is mostly animal and lab work, and no registered human trial has posted results ^[5][6][7].

A Phase 1 trial in healthy volunteers was registered to study safety and pharmacokinetics, meaning how the body takes up and clears the peptide; its status is listed as unknown, with 42 in the enrollment field ^[5]. A randomized, double-blind, placebo-controlled pilot after arthroscopic rotator cuff repair is not yet recruiting, and its registry enrollment field is 30 ^[6]. That pilot plans to assess tendon healing on MRI, patient-reported outcomes, range of motion, strength and blood markers of collagen turnover and inflammation ^[6]. The pilot's own summary states that BPC-157 has not yet been studied in formal human clinical trials ^[6].

In rats with a surgically cut Achilles tendon, the BPC-157 group showed a higher load to failure, better walking-function scores and smaller tendon defects than controls ^[1]. In tissue pieces and cells from rat Achilles tendon, BPC-157 sped cell outgrowth, raised cell survival under oxidative stress and increased cell migration, and the authors linked this to the FAK-paxillin pathway ^[3]. Another rat tendon-cell study found more growth hormone receptor after BPC-157, and the cells then grew more when growth hormone was added ^[8].

In a rat model of alkali skin burns, wounds closed faster and showed more collagen and new tissue at day 18 than in controls ^[10]. The same paper reported that BPC-157 made human umbilical vein cells grow, move and form tube-like structures in a dish ^[10]. In chick embryo membranes and in dishes of blood-vessel cells, BPC-157 increased vessel density, and in rats with reduced blood flow to a hind leg, blood flow recovered faster and more vessels formed ^[4].

In rats given toxic amounts of diclofenac, ibuprofen or celecoxib, those that also received BPC-157 had fewer gut, liver and brain lesions ^[11][12][13]. In rat models where a major vein was tied off or the liver's blood supply was clamped, the research group reported that bypass vessels opened quickly and that clotting and blood-pressure changes were smaller ^[14][15][16]. After both common carotid arteries were briefly clamped in rats, treated rats showed less damage in the hippocampus, a memory area of the brain, and did better on memory and movement tests ^[17]. In rats, BPC-157 was linked to healing of chemically induced colitis and of a bowel join, and to less nerve damage in a toxic model used to study multiple sclerosis ^[18]. These are measured outcomes in animal models, not results in patients ^[7].

Who did the research matters. A 2019 review of soft-tissue studies noted that only a handful of research groups had studied BPC-157 in depth, that most studies used small rodents and that efficacy in humans was yet to be confirmed ^[7]. Many reviews come from the group that first described the peptide, including reviews of its stomach origin, its ties to nitric oxide and its comparison with growth factors ^[19][20][21].

Ellum drafts its research summaries with AI and checks each claim against the cited paper, as How Ellum uses AI explains, and About Ellum says who publishes them. Other peptides are listed in the Peptide Access Index.

More on BPC-157 side effects in animal and lab studies

BPC-157 safety detail comes from animal and lab work, and much of it from the group that first described the peptide ^[19][20]. Reviews by that group report no toxicity in animals and state that a lethal level for 1% of animals (LD1) was not reached ^[19][20]. These are the originating group's own statements about animal work, not independent human data ^[20]. In chicks, BPC-157 caused no tissue or organ damage in short and longer-term toxicity tests ^[22].

Rat and lab studies found effects on blood vessels and blood clotting that remain open questions for people ^{[9][25][26][27]}. In isolated rat aorta, BPC-157 relaxed the vessel through nitric oxide, and the effect grew as the concentration rose ^[9]. In rats, BPC-157 changed blood-pressure responses to drugs that block or feed nitric oxide production, without changing normal blood pressure ^[25]. In rats given aspirin, clopidogrel or cilostazol, BPC-157 largely reversed those drugs' effect on platelet clumping ^[26]. In other rat studies, BPC-157 reduced bleeding time after tail amputation, including in rats given heparin, warfarin or aspirin ^[27]. Whether these effects occur in people who take blood thinners has not been reported in a human trial ^[5][7].

BPC-157 promoted new blood-vessel growth in chick embryo membranes and in rats ^[4]. A review from the originating group notes that new vessel growth is also part of tumor biology ^[28]. The cited animal studies did not test tumor growth ^[4][28].

BPC-157 liver findings come from rats whose livers were injured on purpose ^[11][29]. In rats with tied bile ducts, liver enzyme values and liver damage were lower with BPC-157 ^[29]. In rats given toxic amounts of diclofenac, ibuprofen or paracetamol, liver enzyme values were lower in rats that also received BPC-157 ^[11][12][30]. These are injury models, not tests of liver safety in people ^[7][29]. A lack of reported side effects in rats does not show that BPC-157 is harmless in people ^[7].